Bullous pemphigoid / pemphigoid

• (2022): Balighi K+, Case Rep Dermatol 14(3), 350-355 (4 cases)
• (2022): Prugnit-Rouanet M+, Eur J Dermatol 32(3), 368-372 (40 cases)
• (2020): Silverii GA+, Endocrine 69(3), 504-507 [REVIEW]
• (2020): Yang W+, Diabetes Metab Res Rev Aug, Online ahead of print [REVIEW]

Hypersensitivity

• (2014): Karagiannis T+, Ther Adv Drug Saf 5(3), 138 [REVIEW]

Mucous membrane pemphigoid

• (2023): Thermos G+, Oral Dis 29(5), 2321-2323
• (2021): Suezawa M+, J Dermatol 48(10), 1584-1587 (association)
• (2018): Gaudin O+, Front Immunol May (e-Collection) (association)

Cardiac failure

• (2018): Packer M, JACC Heart Fail Mar, Epub ahead of print [REVIEW]
• (2017): Rehman MB+, Diabetes Metab 43(1), 48 [REVIEW] (increased risk)

Inflammatory bowel disease

• (2018): Greenhill C, Nat Rev Endocrinol Apr, Epub ahead of print

Pancreatitis / acute pancreatitis

• (2025): Jaya Pragadeesh G+, Acta Gastroenterol Belg 88(2), 151-155 [REVIEW]
• (2018): Scheen AJ, Expert Opin Drug Saf Feb, Epub ahead of print [REVIEW]
• (2017): Rehman MB+, Diabetes Metab 43(1), 48 [REVIEW] (increased risk)
• (2014): Karagiannis T+, Ther Adv Drug Saf 5(3), 138 [REVIEW]

Arthralgia

• (2018): Scheen AJ, Expert Opin Drug Saf Feb, Epub ahead of print [REVIEW]

Adverse effects / adverse reactions

• (2026): Lund LC+, Diabetes Res Clin Pract May [REVIEW] (pharmacovigilance / pharmacoepidemiology)
• (2015): Tella SH+, Expert Opin Drug Saf 14(1), 127 [REVIEW]